Study of cediranib and immunotherapy in advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how patients with a certain type of advanced colorectal cancer (MSS-type) feel and do during treatment with a combo of cediranib and immunotherapy. It aims to learn about side effects, quality of life, and how well the treatment works in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced colorectal cancer that has been confirmed as MSS or pMMR type (a type that doesn't have a certain DNA repair problem).
- Your doctor believes you can be treated with a combination of cediranib (a targeted therapy) and an immune checkpoint inhibitor (a type of immunotherapy).
- You are able to clearly answer questions and use a smartphone or device with internet access.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study is looking at how well a combination of medications works for people with advanced colorectal cancer that is microsatellite stable (MSS). The medications include chidamide, a PD-(L)1 inhibitor (a type of immunotherapy), and anti-angiogenic therapy (a treatment that blocks blood vessel growth to tumors).
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.